Angel Romero

📘 𝐓𝐡𝐞 𝟐𝟎𝟐𝟓 𝐑𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐂𝐃𝐌𝐎 𝐑𝐞𝐩𝐨𝐫𝐭 𝐢𝐬 𝐧𝐨𝐰 𝐥𝐢𝐯𝐞. We’ve mapped out what’s really happening behind the wave of new manufacturing/supply claims in RLT. 𝐁𝐞𝐜𝐚𝐮𝐬𝐞 𝐥𝐞𝐭’𝐬 𝐛𝐞 𝐡𝐨𝐧𝐞𝐬𝐭: - Radiopharma CDMO success isn’t about bolting on cleanrooms... - Or securing a few batches of Ac-225. - It’s much more complex. - It's about mastering the full operating system.... - From shielding and decay-timed logistics.... - To dual regulatory pressure and talent nobody can find. 𝐈𝐧𝐬𝐢𝐝𝐞 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭: ✅ Global expansion trends and regional flashpoints ✅ Build vs. buy: who’s acquiring vs. engineering from scratch ✅ Market map of 50+ companies across isotope supply, GMP manufacturing, logistics & more ✅ Case studies on the giants and fast risers: 𝐍𝐨𝐭𝐚𝐛𝐥𝐞 𝐦𝐞𝐧𝐭𝐢𝐨𝐧𝐬: Nucleus RadioPharma | SpectronRx | AtomVie Global Radiopharma Inc. | PharmaLogic | Evergreen Theragnostics | Telix Pharmaceuticals Limited | Novartis | ITM Isotope Technologies Munich SE And many more... Whether you're: - Scaling infrastructure - Investing around it - Or trying to figure out who's going to win.... This unpacks a very complex space and helps to make sense of what's going on. 📩 𝐃𝐫𝐨𝐩 𝐚 𝐜𝐨𝐦𝐦𝐞𝐧𝐭 𝐨𝐫 𝐃𝐌 𝐢𝐟 𝐲𝐨𝐮'𝐝 𝐥𝐢𝐤𝐞 𝐚 𝐜𝐨𝐩𝐲. (Please re-post to help spread the word!!) This is just our read on where this market’s really heading - not advice. #radiopharma #cdmo #theranostics #rlt #biotech #oncology #manufacturing #decayclock

298

145 Comments

Searchends Rx Chem Services is a specialized Talent Acquisition Company dedicated to the Pharmaceutical and Chemical industries. With deep domain expertise and a strong understanding of industry-specific talent requirements, we partner with organizations to identify, attract, and secure high-caliber professionals across all functional areas. Our Industry Focus includes the full value chain of the Pharmaceutical and Chemical sectors: - Active Pharmaceutical Ingredients (API) - Formulations & Finished Dosage - Specialty Chemicals - Bulk Chemicals - Agrochemicals - Petrochemicals - Biotechnology - Research & Development - Contract Manufacturing (CMO/CDMO) We understand regulatory environments such as USFDA, MHRA, EMA, WHO-GMP, and other global compliance standards that influence hiring decisions in these sectors. Our Core Recruitment Expertise encompasses: 1. **Executive & Leadership Hiring**: We assist organizations in recruiting senior leadership professionals including Plant Heads, Site Directors, R&D Heads, QA/QC Leaders, Regulatory Affairs Heads, Operations Directors, and Business Development Leaders. 2. **Technical & Functional Hiring**: We specialize in identifying technically sound professionals in Production & Manufacturing, Quality Assurance & Quality Control, Regulatory Affairs, Research & Development, Engineering & Maintenance, EHS (Environment, Health & Safety), Supply Chain & Procurement, Validation & Compliance, Process Engineering, and Analytical Development. 3. **Lateral & Volume Hiring**: We manage structured hiring programs for Greenfield projects, plant expansions, new product launches, technology transfers, and audit-driven replacement hiring. Our Strengths include: - **Deep Industry Understanding**: We evaluate candidates based on regulatory exposure, audit readiness, technical depth, process knowledge, scale of operations handled, and compliance history. - **Strong Talent Network**: We maintain an extensive database of pre-screened professionals across various levels, from shop-floor specialists to C-suite executives. - **Consultative Approach**: We act as talent advisors, employing detailed requirement mapping, competency-based screening, reference validation, cultural fit assessment, and confidential search Thanks in advance looking for a Sustainable Partnering!!!

10

𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝐰𝐚𝐬 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐚𝐜𝐭𝐢𝐯𝐞 𝐦𝐨𝐧𝐭𝐡𝐬 𝐭𝐡𝐞 𝐂𝐃𝐌𝐎 𝐬𝐞𝐜𝐭𝐨𝐫 𝐡𝐚𝐬 𝐬𝐞𝐞𝐧 𝐚𝐥𝐥 𝐲𝐞𝐚𝐫. 𝐇𝐞𝐫𝐞’𝐬 𝐰𝐡𝐚𝐭 𝐡𝐚𝐩𝐩𝐞𝐧𝐞𝐝. Investments, partnerships and expansions announced this month are shaping next year’s competitive landscape. 🏗️𝐍𝐞𝐰 𝐅𝐚𝐜𝐢𝐥𝐢𝐭𝐢𝐞𝐬 & 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧𝐬: Thermo Fisher Scientific opens an advanced therapies collaboration center in Philadelphia. Piramal Pharma Ltd expands US operations with MHRA GMP certifications and $90M site investment. Hovione commits $100M to double US spray-drying capacity. Simtra BioPharma Solutions grows sterile injectable manufacturing footprint in the US and Europe. Corden Pharma - A Full-Service CDMO'S Colorado site excels with FDA clearance and inspection wins. Lifecore Biomedical and PolyPeptide Group partner on integrated peptide manufacturing solutions. Bora Pharmaceuticals adds oncology isolator lines for high-potency drug supply. Aenova Group launches new sterile biologics fill & finish line 🤝𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬 & 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧𝐬: AGC Biologics advances multiple viral vector and mRNA therapy manufacturing agreements. Andelyn Biosciences secures global licensing with Solid Biosciences for gene therapy. Cellipont Bioservices deepens cell therapy manufacturing with Ronawk and Ernexa Therapeutics partnerships. WuXi AppTec broadens CRDMO scope with key international MoUs. Abzena and Mabqi Labs team up for integrated antibody CDMO services. BIOVECTRA strengthens mRNA CDMO capabilities through partnership with Revolution Biomanufacturing Inc.. SK pharmteco invests significantly in US peptide development. ⚙️ Technology & Innovation Launches: Ascend Advanced Therapies unveils enhancers boosting AAV production yields by 3x. Vector BioMed, Inc. expands lentiviral vector LENTIVERSE™ platform and launches new branding. Touchlight enhances circular DNA architectures for next-gen gene therapy manufacturing. 🌍 Global Partnerships Driving Regional Expansion: Wheeler Bio, Inc. teams with Mitsubishi Corporation to extend CDMO reach in Asia-Pacific. AtomVie Global Radiopharma Inc. Global Radiopharma supports cutting-edge radiopharmaceutical clinical trials. This level of activity is already shaping US hiring needs in ops, quality, tech development and commercial teams. Which move do you think will have the biggest impact? #CDMO #Pharma #Biotech #Manufacturing #CellTherapy #GeneTherapy #AdvancedTherapies #Investments #BusinessDevelopment

48

Tandem Diabetes Care Q2 2025 Highlights: ✅ Beat revenue expectations ✅ Shipped more pumps in the U.S. ✅ Launched early access for t:slim X2 + Libre 3 ✅ Earned CE Mark for Mobi with Control-IQ+ ✅ Submitted extended wear SteadiSet to the FDA ✅ Advanced fully closed-loop system On track to reach $1 billion in global revenue this year — a major milestone for Tandem Diabetes Care. #TandemDiabetesCare #Diabetes #MedTech #MRSLC

46

EXCLUSIVE: Inside VedaBio - The Breakthrough That Could Redefine Point-of-Care Diagnostics - Frederic D. Sweeney, Chief Executive Officer In this episode of Diagnosing Dx, I sit down with Frédéric D. Sweeney, President & CEO of VedaBio, the company pioneering a completely new class of molecular diagnostics — one that detects DNA and RNA without amplification while maintaining full clinical sensitivity in under 10 minutes.   We explore how this platform could transform urgent care, decentralised testing, and infectious disease workflows — and why VedaBio believes the next leap in molecular diagnostics won’t come from making PCR faster, but from removing amplification entirely.   Frédéric also opens up about the realities of transitioning from feasibility to product development, building the right team, navigating today’s funding climate, and why 2026 is shaping up to be a pivotal year for the company. 🔥Takeaways 🔹Why removing amplification could reshape point-of-care diagnostics 🔹How patient experience drives VedaBio’s product vision 🔹The importance of strategic partnerships during early scaling 🔹What founders need to know about fundraising and team building in today’s diagnostics market   🎧 Listen/watch now on: 🔹 YouTube: https://lnkd.in/edyzZjD7 🔹 Spotify: https://lnkd.in/exc-C-Gc 🔹 Apple: https://lnkd.in/eB5DqBaY 🔔 If you want to be alerted of new Diagnosing Dx episodes straight to your email inbox sign up here: https://lnkd.in/eQ4cebZv

22

9 Comments

Clinical development is shifting toward proactive risk management, innovative trial design, and faster delivery of therapies. Companies are focusing on readiness and adaptability to navigate evolving regulations and patient expectations. These strategies improve efficiency while ensuring safety and compliance. The future of drug development relies on agility, foresight, and strategic planning. #ClinicalDevelopment #DrugInnovation https://lnkd.in/eAAei-Y9 

5

The biosensors market is booming! From just $30 billion in 2024, it's projected to grow to $75.2 billion by 2035, with an impressive CAGR of 8.75%. The key drivers? Rising chronic disease cases and the need for continuous monitoring. Wearable devices are at the forefront, integrating with AI for even smarter diagnostics. However, high production costs and regulatory hurdles still pose significant challenges. Yet, the potential for growth, especially in North America, is undeniable. #Biosensors #Medtech #WearableTech

34

Case study Client: Biotech company scaling manufacturing Challenge: Couldn’t find qualified process development experts(8 roles)>100 applicants Solution: Targeted niche sourcing + market calibration Result: Reduced time-to-fill by ~40% Specialized roles require specialized strategies. #lifesciencesolutions #scaling #consultativeapproach

1

🚀💉 Tubulis GmbH bags $120M Series C – Merck’s backing the best-in-class ADC formula that’s finally cracked! 🌟🔬 Led by Nextech & Andera, the round fuels TUB-040 (Napi2b ADC) into Phase 2 for ovarian & lung cancer, plus TUB-050 (NaPi2b x CD3 bispecific) & a deep preclinical pipeline. With superior stability, tumour-specific payload release, and plug-and-play conjugation, Tubulis’ P5 & WPB tech promises wider therapeutic windows and higher potency than legacy ADCs. Merck’s $700M+ prior collab? Now they’re all-in on the platform! 💰✨ “We have solved the ADC formula – stable linkers, tumour-selective activation, and flexible conjugation for truly differentiated medicines.” – Dominik Schumacher, Tubulis CEO, on rewriting oncology! 🔥🧪 ADC 3.0 is here! 🤔 Who’s next to leap ahead? Tag an oncology innovator & let’s forecast the winners! 👇💬

9

1 Comment

𝐌𝐨𝐧𝐝𝐚𝐲 𝐌𝐢𝐧𝐮𝐭𝐞 ⏱️ ⠀ Recent industry reporting (MedTech Dive) indicates that staffing constraints at the FDA are contributing to slower review timelines, with smaller medtech companies seeing the most impact. ⠀ When review cycles extend, the submission process typically involves: • additional documentation • more revision cycles • longer coordination across internal teams ⠀ In regulated environments, timelines are not just driven by innovation — they are influenced by capacity at both the company and agency level. ⠀ A dynamic worth watching as the year progresses. ⠀ #MedTech #FDA #Regulatory #MedicalDevices #IndustryTrends Julie Grey Grey Staffing

1

Operational Excellence – Why It Matters Operational excellence at SRG is more than just efficient processes; it’s a disciplined, data-driven commitment to delivering exceptional value to our clients in the pharmaceutical, biotechnology, and medical technology industries. Our innovative approach to talent delivery aligns people, processes, and technology to meet regulatory demands, accelerate innovation, and build scalable talent pipelines for highly specialized roles. Discover how we drive performance for our clients in the life sciences sector, and read this blog penned by Patrick H. Stedman. https://lnkd.in/e74wtPvY #WorkforceManagement #LifeSciencesStaffing #OperationalExcellence #TalentDelivery

7

𝐏𝐡𝐚𝐫𝐦𝐚 & 𝐂𝐃𝐌𝐎 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐅𝐚𝐜𝐢𝐥𝐢𝐭𝐲 𝐆𝐫𝐨𝐰𝐭𝐡 (𝐔𝐒 & 𝐄𝐔) 🌎 𝐔𝐧𝐢𝐭𝐞𝐝 𝐒𝐭𝐚𝐭𝐞𝐬 𝐔𝐩𝐝𝐚𝐭𝐞𝐬 🌍 Novartis is investing $23 billion over five years to build seven new US facilities, expand existing ones, and open a $1.1 billion R&D institute in San Diego. This supports radioligand therapy sites in FL and TX, with 5,000 jobs projected. Eli Lilly and Company Lilly is evaluating a $5.9 billion biomanufacturing campus in Houston to produce active pharmaceutical ingredients—potentially creating 600+ permanent roles and 2,000+ construction jobs. Roche / Genentech is building a $700 million plant in Holly Springs, NC, focused on obesity therapies, and investing $550 million in Indianapolis for glucose-monitoring production. Roche plans to invest $50 billion in the US by 2030. National Resilience, Inc. is investing $225 million to scale fill-finish capacity across Cincinnati and RTP, targeting over 200 million units/year by 2025. LGM Pharma is expanding its Rosenberg, TX site with a $6 million investment for liquids, semi-solids, topicals, and suppositories. 🌍 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 🌍 Corden Pharma - A Full-Service CDMO is expanding its GLP‑1 peptide production across Europe under the same €900M program. SEKISUI Diagnostics has completed a £15.7 million cGMP expansion for microbial fermentation, scaling up to 1,000 L production. Simtra BioPharma Solutions is investing over €230M in sterile fill–finish plants in both Ravensburg and Bloomington, with clinical lines expected online by summer 2025. Cambrex has doubled API capacity in North Carolina with a $38M upgrade, alongside a $100M global expansion including sites in Italy, Belgium, and Boston. 𝘎𝘳𝘦𝘢𝘵 𝘵𝘰 𝘴𝘦𝘦 𝘴𝘰 𝘮𝘶𝘤𝘩 𝘮𝘰𝘮𝘦𝘯𝘵𝘶𝘮 𝘢𝘯𝘥 𝘪𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘪𝘯𝘵𝘰 𝘮𝘢𝘯𝘶𝘧𝘢𝘤𝘵𝘶𝘳𝘪𝘯𝘨, 𝘢 𝘱𝘰𝘴𝘪𝘵𝘪𝘷𝘦 𝘴𝘪𝘨𝘯 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘪𝘯𝘥𝘶𝘴𝘵𝘳𝘺! 

7

1 Comment

#LeftAtrialAppendageClosureDeviceIndustry..... What's it all about? Reaching USD 3.91 billion in 2024, further expanding to USD 38.62 billion by 2032. Increasing FDA approvals, adoption of minimally #invasivecardiacprocedures, and improved reimbursement frameworks are accelerating the industry’s growth trajectory. Who are the major global players in this market? #projectusconsulting #topcardiactglobaltalent #gettingtotheheartofthematter

5

Large firms bring scale. Boutique firms bring signal. In life sciences recruiting, nuance matters: • Regulatory pathway experience • Modality expertise • Phase-specific leadership • Scientific credibility We don’t just scan resumes, we understand pipelines, platforms, and pressure points. In highly specialized markets, precision beats volume. #precision #lifesciences

8

3 Comments

!!!!  𝗝𝗢𝗕 𝗠𝗔𝗥𝗞𝗘𝗧 𝗨𝗣𝗗𝗔𝗧𝗘 𝟭𝟬/𝟮𝟬/𝟮𝟱 !!!! As of mid-October 2025, the pharmaceutical and biotech industries are on track to surpass 60,000 employees laid off in 2025 by year-end, marking one of the steepest annual workforce reductions in the life sciences sector in over a decade.​ Key 2025 Layoff Trends Biopharma Layoffs: There have already been 128 biotech and pharma layoff rounds in the first half of 2025, a 32% jump from 2024. This pace puts the sector on track to exceed 200 layoffs total for the year, surpassing 2024’s full-year record of 192.​ May 2025 alone saw 29 separate reductions-in-force, the highest monthly total on record for this industry.​ Total Employees Affected: Just six major pharmaceutical firms including Bristol Myers Squibb, Merck, Genentech, Novartis, and Pfizer, are collectively responsible for a STAGGERING nearly 39,000 job cuts so far, primarily through site consolidations, R&D restructuring, and post-patent cost savings.​ Factoring in smaller biotech layoffs, analysts estimate the total employee impact could reach 60,000–65,000 by year-end 2025.​ Driving Factors: Patent cliffs (e.g. Eliquis, Opdivo, Keytruda) are forcing cost realignments. AI integration and automation are streamlining early drug discovery and data functions, reducing human headcount.​ VC funding slowdown (down ~20% year-over-year) continues to strain smaller biotechs, forcing mergers, asset sales, or shutdowns.​ Focus shift to later-stage and revenue-generating assets has deprioritized early pipeline projects and associated teams.​ Outlook Analysts expect the layoff wave to persist into early 2026, fueled by further strategic realignments, continued capital constraints, and AI-driven efficiency initiatives. The most vulnerable segments remain preclinical biotechs and mid-tier commercial organizations without late-stage or monetized portfolios.​ In short, 2025 has already cemented itself as a year of historic restructuring across the life sciences workforce, layoffs surpassing even the post-2020 correction levels. If you factor in globally located people, the number is 80,000-85,000 impacted. NOTE: if you are on the market, there are still jobs to be had. You must remain optimistic and persistent. Tailor your job search to the jobs that fit your most recent experience the best as that is where you will shine the most. If you are going for jobs where you have experience from 5 years ago, you will be up against a slate of candidates that are CURRENTLY doing the job. You will stand-out the most with your current experience. Don't give up. Stay positive and keep at it. #NotTheNewsYouWantToHear #PharmaIndustryUpdate

459

50 Comments

Strategic life sciences marketing agency ramarketing has completed the acquisition of ISR Market Research, a specialist agency based in North Carolina's Research Triangle Park (RTP), one of the largest pharmaceutical and biopharma hubs in North America. The move brings together ISR's research and insight capability with ramarketing's strategy, marketing, and communications expertise. The combined capabilities will support clients from evidence generation and market insight through to positioning, go-to-market strategy and activation. Congratulations to all involved, exciting times ahead!! Emma Banks Yasmin Davoodi Melissa Pattinson NorthEdge Raman Sehgal

39

AACR 2026: From "Following the Trend" to "Driving Clinical Value" — Join us in San Diego! The newly released AACR 2026 abstracts (9,500+ across 40+ countries) have sent a clear signal to the global oncology market: The era of "hype-driven" drug development is over. We are officially entering a Value Reconstruction Phase. Key Takeaways from the 2026 Data: 💊 ADC Differentiation: With 355 abstracts, ADCs are moving beyond HER2/TROP2 "red oceans" into bispecific and multi-payload innovations (e.g., CDH17, CD276). 💡 The KRAS Evolution: Chinese-originated assets like elisrasib are making history on the Plenary stage, proving that China is no longer just "fast-following" but "co-leading." 💸 BD Strategic Shift: Over 52% of clinical assets are in Phase I/II, marking a golden window for early-stage cross-border dealmaking. To navigate this complex landscape, IntelliPro Group is proud to support this high-level executive forum hosted by Jones Day, AHEA, and USCACA on the sidelines of AACR 2026. 📅 Theme: Accelerating Oncology Drug Development by Leveraging US–China Collaboration ⏰ Time: April 16, 2026 | 3:00 PM – 7:00 PM (PT) 📍 Venue: Jones Day – San Diego Office (4655 Executive Dr.) Why Attend? We’ve assembled an elite lineup of speakers from Daiichi Sankyo, Pfizer, Geron, Aureka Biotech etc. alongside IP and M&A experts from Jones Day. We will dive deep into: Leveraging China’s Early-Stage IIT Programs to accelerate translational oncology. Building the Next-Generation Oncology Pipeline through precision, partnership, and purpose. This is a private executive gathering designed for decision-makers. Spaces are limited and filling up fast. DM me for an invite. Let’s connect in San Diego and shape the future of oncology together! #AACR2026 #Oncology #Biotech #LifeSciences #DrugDevelopment #USChinaCollaboration #BusinessDevelopment #IntelliPro #Networking #PharmaInnovation #ADC #KRAS

6